Wertheimer Samuel P 4
4 · Apexigen, Inc. · Filed Aug 25, 2023
Insider Transaction Report
Form 4
Apexigen, Inc.APGN
Wertheimer Samuel P
DirectorChief Executive Officer
Transactions
- Disposition to Issuer
Warrants (right to buy)
2023-08-23−1,845→ 0 totalExercise: $1.75Exp: 2028-08-21→ Common Stock (1,845 underlying) - Disposition to Issuer
Warrants (right to buy)
2023-08-23−12,383→ 0 totalExercise: $11.50Exp: 2027-07-29→ Common Stock (12,383 underlying) - Disposition to Issuer
Common Stock
2023-08-23−146,383→ 0 total - Disposition to Issuer
Stock Option (right to buy)
2023-08-23−100,000→ 0 totalExercise: $2.65Exp: 2032-09-29→ Common Stock (100,000 underlying)
Footnotes (4)
- [F1]Pursuant to an Agreement and Plan of Merger, dated as of May 23, 2023 (the "Merger Agreement"), by and among the Issuer, Pyxis Oncology, Inc. ("Pyxis"), and Ascent Merger Sub Corp., at the effective time of the merger (the "Effective Time"), each share of Issuer common stock was exchanged for 0.1725 shares of Pyxis common stock and rounded down to the nearest whole share.
- [F2]The shares subject to the option vest in three equal annual installments beginning on July 29, 2023. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 17,250 shares of Pyxis common stock at an exercise price of $15.37 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time.
- [F3]The shares underlying the warrant are immediately exercisable. Pursuant to the Merger Agreement, at the Effective Time, the warrant was assumed by Pyxis and converted into a warrant to purchase 2,136 shares of Pyxis common stock at an exercise price of $66.67 per share.
- [F4]The shares underlying the warrant are immediately exercisable. Pursuant to the Merger Agreement, at the Effective Time, the warrant was assumed by Pyxis and converted into a warrant to purchase 318 shares of Pyxis common stock at an exercise price of $10.15 per share.